Be the first to review this item
Cardiomagnyl has an antiaggregant effect, is a non-steroidal anti-inflammatory agent. The anti-inflammatory effect is associated with irreversible inhibition of cyclooxygenase-1 due to the acetylation reaction. Thromboxane A2 under the influence of acetylsalicylic acid (ASA) decreases as a result of selective inhibition of its synthesis. Probably, there are other mechanisms to reduce platelet aggregation under the action of ASA.
Magnesium hydroxide has a protective effect on the gastric mucosa, which is important when taking ASA.
ASA is completely absorbed when taken orally from the gastrointestinal tract. Hydrolysis to salicylic acid occurs with the participation of esterases in the liver, intestine and blood plasma. The half-life of ASA is 15 minutes, salicylic acid is 3 hours. Additional administration of ASA (more than 3 g) can prolong the half-life of salicylic acid due to the full saturation of enzyme systems. Bioavailability of the metabolite ASA - salicylic acid - is from 80 to 100%. Bioavailability of ASA is approximately 70%, but this value is very variable due to presystemic hydrolysis in the wall of the stomach, intestine and liver tissue. Magnesium hydroxide in the cardiomagnum does not affect the bioavailability of ASA.
With caution should prescribe the drug for gout, hyperuricemia, the presence of an anamnesis of gastrointestinal lesions or bleeding from the gastrointestinal tract, with renal and / or liver failure, bronchial asthma, hay fever, nasal polyposis, allergic conditions, in the second trimester of pregnancy.
1 tablet of cardiomagnet-forte or 2 tablets of cardiomagnesium (150 g ASA) on the first day of treatment, then - 75 mg (1 tablet of cardiomagnesium) 1 time per day. The tablet is washed down with a small amount of water. If necessary, the tablets are chewed or crushed. It is recommended to eat after eating. Duration of treatment is determined by the doctor individually depending on the clinic, indications and severity of the disease.
Take the drug Cardiomagnyl should be after the appointment of a doctor.
Acetylsalicylic acid can provoke bronchospasm, as well as cause attacks of bronchial asthma and other reactions of hypersensitivity. Risk factors are the presence of bronchial asthma in history, hay fever, nasal polyposis, chronic diseases of the respiratory system, as well as allergic reactions (for example, skin reactions, pruritus, urticaria) to other drugs.
Acetylsalicylic acid can cause bleeding of varying severity during and after surgical interventions.
A few days before the planned surgery, the risk of bleeding should be assessed compared with the risk of developing ischemic complications in patients taking low doses of acetylsalicylic acid. If the risk of bleeding is significant, the intake of acetylsalicylic acid should be temporarily discontinued.
The combination of acetylsalicylic acid with anticoagulants, thrombolytics and antiplatelet drugs is accompanied by an increased risk of bleeding.
The intake of acetylsalicylic acid in low doses can provoke the development of gout in predisposed individuals (having decreased uric acid excretion).
The combination of acetylsalicylic acid with methotrexate is accompanied by an increased incidence of side effects from the hematopoiesis.
Acetylsalicylic acid in high doses has a hypoglycemic effect, which must be borne in mind when prescribing it to patients with diabetes mellitus receiving hypoglycemic agents for ingestion and insulin.
When combined use of systemic GCS and salicylates should be remembered that during treatment, the concentration of salicylates in the blood is reduced, and after the abolition of systemic SCS, an overdose of salicylates is possible.
It is not recommended to combine acetylsalicylic acid with ibuprofen in patients with an increased risk of cardiovascular disease: when combined with ibuprofen, a decrease in the antiplatelet effect of acetylsalicylic acid in doses up to 300 mg is observed, which leads to a decrease in the cardioprotective effects of acetylsalicylic acid.
Exceeding the dose of acetylsalicylic acid with more recommended therapeutic doses is associated with a risk of gastrointestinal bleeding.
With long-term use of acetylsalicylic acid in low doses as antiplatelet therapy, caution is needed in elderly patients due to the risk of developing gastrointestinal bleeding.
With the simultaneous administration of acetylsalicylic acid with ethanol, the risk of damage to the mucosa of the gastrointestinal tract and prolonging the time of bleeding is increased.
Impact on the ability to drive vehicles and manage mechanisms
During treatment with acetylsalicylic acid, patients should be careful when driving vehicles and engaging in potentially dangerous activities that require a high concentration of attention and speed of psychomotor reactions.
Important notice- the outer box design may vary before prior notice!
Someone from the France - just purchased the goods:
Vitamin B-Complex 100mg injection 10 vials